Close

Walter Reinisch, MD

Professor, Division of Gastroenterology, Department of Medicine

Chairholder, Audrey Campbell Chair in Ulcerative Colitis Research

Associate Professor, Gastroenterology, Division of Gastroenterology & Hepatology, Medical University of Vienna

Email: reinisw@mcmaster.ca

Dr. Reinisch, MD, graduated at the Medical University of Vienna (MUV), where he finished his training in Internal Medicine and Gastroenterology. After initial scientific studies in oncology at the MUV and the National Cancer Institute, Frederick, MD, he decided to focus his research interest on inflammatory Bowel disease (IBD). Dr. Reinisch is founding member of the European Crohn’s & Colitis Organisation (ECCO) and was assigned as honorary member after having contributed in various positions. He was active in the Scientific and Public Affairs Committee of the United European Gastroenterology (UEG) and headed the Austrian IBD Study Group. Dr. Reinisch is member of the International Organization For the Study of Inflammatory Bowel Disease (IOIBD).

Dr. Reinisch is an expert in designing, conducting and interpreting the results of clinical trials in IBD. He envisions a customized management of IBD utilizing the innovations of translational medicine. He advocates the implementation of a “common language of inflammatory bowel disease” to improve the communication with patients and between physicians for a better care and more robust research outcomes.

  1. Reinisch, W, Gibson, PR, Sandborn, WJ, Feagan, BG, Strauss, R, Johanns, J et al.. Long-term Benefit of Golimumab for Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from the PURSUIT-Maintenance Extension. J Crohns Colitis. 2018; :. doi: 10.1093/ecco-jcc/jjy079. PubMed PMID:29917070 .
  2. Narula, N, Alshahrani, AA, Yuan, Y, Reinisch, W, Colombel, JF. Patient-Reported Outcomes and Endoscopic Appearance of Ulcerative Colitis-a Systematic Review and Meta-Analysis. Clin. Gastroenterol. Hepatol. 2018; :. doi: 10.1016/j.cgh.2018.06.015. PubMed PMID:29913273 .
  3. Rüland, AM, Hagemann, F, Reinisch, M, Holtschmidt, J, Kümmel, A, Dittmer-Grabowski, C et al.. Using a New Marker Clip System in Breast Cancer: Tumark Vision® Clip - Feasibility Testing in Everyday Clinical Practice. Breast Care (Basel). 2018;13 (2):116-120. doi: 10.1159/000486388. PubMed PMID:29887788 PubMed Central PMC5981593.
  4. D'Haens, G, Reinisch, W, Panaccione, R, Satsangi, J, Petersson, J, Bereswill, M et al.. Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry. Am. J. Gastroenterol. 2018; :. doi: 10.1038/s41395-018-0098-4. PubMed PMID:29867173 .
  5. Reinisch, W, Hung, K, Hassan-Zahraee, M, Cataldi, F. Targeting endothelial ligands: (ICAM-1/Alicaforsen, MAdCAM-1). J Crohns Colitis. 2018; :. doi: 10.1093/ecco-jcc/jjy059. PubMed PMID:29757363 .
  6. GlobalSurg Collaborative. Laparoscopy in management of appendicitis in high-, middle-, and low-income countries: a multicenter, prospective, cohort study. Surg Endosc. 2018; :. doi: 10.1007/s00464-018-6064-9. PubMed PMID:29623470 .
  7. Schwarz, E, Reinisch, G, Brandauer, A, Aharinejad, S, Scharf, W, Trieb, K et al.. Load transfer and periprosthetic fractures after total hip arthoplasty: Comparison of periprosthetic fractures of femora implanted with cementless distal-load or proximal-load femoral components and measurement of the femoral strain at the time of implantation. Clin Biomech (Bristol, Avon). 2018;54 :137-142. doi: 10.1016/j.clinbiomech.2018.03.010. PubMed PMID:29587147 .
  8. Patuzzi, GC, Lira, APS, Santos, JDM, Reinisch, AOB, Veleda, AA. Academic learning about public health in a Canadian university: contributions for Brazilian education. Rev Gaucha Enferm. 2018;38 (3):e0012. doi: 10.1590/1983-1447.2017.03.2016-0012. PubMed PMID:29538605 .
  9. Ehrenkranz, PD, Calleja, JM, El-Sadr, W, Fakoya, AO, Ford, N, Grimsrud, A et al.. A pragmatic approach to monitor and evaluate implementation and impact of differentiated ART delivery for global and national stakeholders. J Int AIDS Soc. 2018;21 (3):. doi: 10.1002/jia2.25080. PubMed PMID:29537628 PubMed Central PMC5851343.
  10. Miehsler, W, Dejaco, C, Gröchenig, HP, Fuchssteiner, H, Högenauer, C, Kazemi-Shirazi, L et al.. [Second Austrian consensus on the safe use of anti-TNFα-antibodies in patients with inflammatory bowel diseases]. Z Gastroenterol. 2018;56 (3):275-302. doi: 10.1055/s-0044-100044. PubMed PMID:29529682 .
Search PubMed
Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedIn